ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2304

Joint Injection Practices in Pediatric Rheumatology – Preliminary Data from an Ongoing Web Based Survey

Anita Dhanrajani1 and Raju Khubchandani2, 1Rheumatology, Vasculitis Research Fellow - HSC, Toronto, ON, Canada, 2Department of Paediatrics, Jaslok Hospital and Research Center, Mumbai, India

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Arthrocentesis and juvenile arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Corticosteroid joint injections are a routine procedure in pediatric rheumatology. The dearth of existing literature on current practices led the authors to conduct an online survey targeting pediatric rheumatologists in Europe and North America.

Methods: An electronic survey with 22 questions related to pre-procedural sedation, choice of anesthetic agent, dose and type of therapeutic agent, number of joints injected, use of ultrasound, and post procedure complications was designed with a web based survey engine – Survey Monkey. The survey was distributed via email to physicians registered in the PRINTO and CARRA/PRCSG networks.

Results: 187/213 respondents (Table 1) performed joint injections as a routine clinical practice, of which 110 (57.6%) had received formal training in the procedure. 51.1% procedures were performed as an outpatient, either in a procedure room, day care or minor operation room. 152/180 respondents (85.5%) injected multiple joints in one sitting. Less than half physicians (45%) resort to ultrasound guidance, most often for the hip joint. Ignoring availability, triamcinolone hexacetonide (TH) was the most preferred agent by 79.6% of respondents. Other agents were Triamcinolone acetonide, Methylprednisolone acetate, hydrocortisone acetate and betamethasone acetate, in order of frequency. Only 51.5% physicians said that TH was consistently available in their country. There was some consensus about the dose of steroid (TH equivalent) as 1 mg/kg for large joints (62.9%), but wide variation in the dose for smaller joints. 65.9% physicians resorted to local anesthesia, including EMLA cream, subcutaneous Lidocaine, Lidocaine spray, ethyl chloride spray or a combination. Intravenous sedation was used by more than half physicians (51.2%), oral sedation by 15.7%, long anesthesia by 2.4% and other methods by 30.7%

Most respondents experienced some procedural complications in their clinical experience, commonest being subcutaneous atrophy(Table 2). Most physicians recommended home ambulation for 24-48 hours after procedure, however some variations such as complete bed rest, splinting, immobilization, and rest for longer than 48 hours were observed. 48.2% respondents follow significantly different practices in 0-5 year age group, for either choice of anesthesia, setting of procedure, use of ultrasound guidance or number of joints injected.

Conclusion: Practices related to pediatric joint injection procedures are not uniform and methods to develop standardization of this extremely common procedure is the need of the hour.

Table 1:

Geographical Location of training

Percentage (n)

Europe

34.5(38)

UK*

8.2 (9)

Australia

1.8 (2)

Asia

1.8 (2)

India

0

USA**

37.3 (41)

Canada

16.4 (18)

Others

0

*UK – United Kingdom

**USA – United states of America

Table 2:

Complication

Frequency (n)

Subcutaneous atrophy

78.9 (131)

Iatrogenic infection

1.8 (3)

Anesthetic complications

4.8 (8)

Tendon rupture

1.2 (2)

Fat necrosis or calcification

24.7 (41)

Local bleeding

10.2 (17)

None

19.3 (32)

Other

9.0 (15)


Disclosure: A. Dhanrajani, None; R. Khubchandani, None.

To cite this abstract in AMA style:

Dhanrajani A, Khubchandani R. Joint Injection Practices in Pediatric Rheumatology – Preliminary Data from an Ongoing Web Based Survey [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/joint-injection-practices-in-pediatric-rheumatology-preliminary-data-from-an-ongoing-web-based-survey/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/joint-injection-practices-in-pediatric-rheumatology-preliminary-data-from-an-ongoing-web-based-survey/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology